Shots:

• The P-II study involves assessing of Bavencio in 15 women (median age 34yrs.) with GTT that are resistant to mono-CT. All patients had progressed on treatment with MTX; one patient had progressed on actinomycin-D. while patients received Bavencio until hCG levels returned to normal- followed by 3 additional cycles
• Results: 8/15 patients had no sign of disease relapse @29mos. follow-up. & hCG levels returned to normal and have been maintained- if disease has not relapsed @12mos. & monitoring of hCG has concluded- the patient is considered cured- Bavencio showed resistance in the remaining  7 patients (47%)- requiring CT with actinomycin-D/ polychemotherapy with/out surgery
• The study suggested that Bavencio may work as a potential therapy for GTT patients. The study is the first study exploring use of immunotherapy in patients with GTT

Click here ­to­ read full press release/ article | Ref: ASCO | Image: CHE Manager